GlassScriptPhysician profile
Iyad N Daher
NPI 1154544005
$981.52
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $142 · 2021: $277 · 2022: $146 · 2023: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $177.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.02 | 2019-2023 | Lifevest |
| Amgen INC. | $170.48 | 2020-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $125.13 | 2020-2023 | Farxiga |
| Cvrx, INC. | $95.65 | 2023 | Barostim Neo System |
| Abbott Laboratories | $86.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $81.38 | 2021-2022 | |
| Amarin Pharma, INC. | $68.05 | 2020-2021 | |
| Pfizer INC. | $47.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.05 | 2019 | |
| Lilly USA, LLC | $21.79 | 2019 | |
| Boston Scientific Corporation | $17.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.86 | 2021 | |
| Edwards Lifesciences Corporation | $12.95 | 2023 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iyad Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.